The clinical benefit observed with the combination of osimertinib and selpercatinib highlights the therapeutic potential of targeting acquired gene fusions in EGFR-mutant NSCLC and underscores the growing importance of repeat molecular profiling at the time of disease progression. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.